Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COX-2 alteration in advanced colon cancer treated with capecitabine versus 5-fluorouracil and calcium folinate (Mayo regimen) combination
2005-003646-34Phase 4Completed
- Sponsor
- Klaipėda University Hospital
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of capecitabine in colon cancer (2 arms), sponsored by Klaipėda University Hospital. Primary endpoints: Plasma COX-2 concentration change and Safety and toxicity of capecitabine versus Mayo regimen. Started Aug 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2005-003646-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003646-34.